Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia
| Autor: | Flavio Albarracin, Maurizio Miglino, Giovanna Piaggio, Sarah Pozzi, Francesca Bertolotti, Andrea Bacigalupo, Alida Dominietto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Acute leukemia
medicine.medical_specialty Myeloid business.industry Lymphocyte Minimal residual disease donor lymphocyte infusion Hematology acute myeloid leukemia medicine.disease Gastroenterology Donor lymphocyte infusion Surgery body regions Leukemia Graft-versus-host disease medicine.anatomical_structure Internal medicine hemic and lymphatic diseases medicine Cumulative incidence allogeneic hematopoietic stem cell transplantation business acute lymphoid leukemia |
| Zdroj: | Revista Brasileira de Hematologia e Hemoterapia v.30 suppl.2 2008 Revista brasileira de hematologia e hemoterapia Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) instacron:ABHHTC |
| Popis: | Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR gene re-arrangement for ALL, and Wilm's Tumor (WT1) expression for AML. The overall cumulative incidence (CI) of MRD was positive in 45% and the CI of hematologic relapse was 24% (36% in MRD+ vs. 16% in MRD patients, p=0.03). The median interval from transplant to first MRD positivity was 120 days and to hematologic relapse 203 days. Patients were divided in 3 MRD groups: MRD (n=44), MRD+ given donor lymphocyte infusions (DLI) (n=17) and MRD+ not given DLI (n=19): leukemia relapse rates in these 3 groups were 16%, 6% and 63%, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|